Manminder S Bhullar, MD
Cardiovascular Disease (Cardiology) · Clovis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 20 years
- Graduated 2006
Offices
4 locations · Fresno Community Hospital and Medical Center · California Heart Medical Associates, Inc
Hospitals listed: Adventist Health Hanford · Clovis Community Medical Center · Community Regional Medical Center · Kaweah Health Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhullar’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A123839 · Current
Licensed to practise in California · since 2012 · expires 2028-05-31 · Baba Farid University of Health Sciences, Government Medical College, Amritsar.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Interventional Cardiology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health HanfordHanford, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.277, Oct 2024 – Sep 2025
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Kaweah Health Medical CenterVisalia, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Kaweah Delta Health Care DistrictPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 239.86 (194.11 to 285.6) · 104 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Hanford
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.277 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 614 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.38 to 1.15) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 190.5 (130.11 to 250.89) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.4 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 269 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.8 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.2 · 145 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,486 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,684 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 3,819 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.67 (0.36 to 4.98) · 613 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.32) · 154 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.65 (1.02 to 4.28) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.24 (0 to 16.19) · 160 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (0.67 to 9.03) · 147 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 1) · 3,186 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.418 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.574 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 38 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 14.5 · 302 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22 · 380 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 407 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 113 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10 to 17) · 896 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 228 cases | No different | Jan 2024 – Dec 2024 |
What patients said (947 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Kaweah Health Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 3 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 239.86 (194.11 to 285.6) · 104 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.22 (0.28 to 2.16) · 1,600 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.53 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.8 · 626 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.1 · 741 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 373 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,927 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.38) · 9,267 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.81 to 5.63) · 2,251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.53 to 3.61) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.45 to 3.13) · 2,231 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.88 (1.1 to 12.66) · 799 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.59 (0 to 7.19) · 759 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 416 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 0.89) · 8,159 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 43 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.728 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.023 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.551 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 344 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 799 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17 · 286 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 31.4 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6 · 734 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.6 to 7.6) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.9 (6.6 to 11.9) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 317 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.3 to 14) · 1,748 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 680 cases | No different | Jan 2024 – Dec 2024 |
What patients said (435 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$404,483
Medicare paid this office $404,483 for 3,656 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 118 | $83,342 | $683 |
| Return visit (30+ min) | 297 | $59,547 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 204 | $33,425 | $151 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 96 | $33,270 | $347 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 3,195 | $24,670 | $6 |
See all 31 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 118 | $83,342 | $683 |
| Return visit (30+ min) | 297 | $59,547 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 204 | $33,425 | $151 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 96 | $33,270 | $347 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 3,195 | $24,670 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 292 | $16,321 | $52 |
| New patient visit (45+ min) | 142 | $14,957 | $105 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 97 | $14,786 | $76 |
| Ultrasound of both sides of head and neck blood flow | 87 | $13,388 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $11,761 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $11,637 | $134 |
| Critical care, first 30-74 minutes | 27 | $11,179 | $164 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 54 | $10,674 | $198 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $8,182 | $431 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 113 | $5,936 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 96 | $5,005 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 262 | $3,154 | $10 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 118 | $2,185 | $18 |
| Short return visit (20+ min) | 29 | $1,982 | $64 |
| Long return visit (40+ min) | 11 | $1,893 | $146 |
| Injection, regadenoson, 0.1 mg | 75 | $1,852 | None |
| Insertion of tube in right heart chambers for measurement | 11 | $1,168 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,075 | $83 |
| Ultrasound of heart, follow-up | 52 | $1,011 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $924 | $62 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 90 | $885 | $9 |
| Ultrasonic guidance for blood vessel access | 53 | $576 | $11 |
| Injection, aminophyllin, up to 250 mg | 75 | $491 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 52 | $288 | $5 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $208 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 62 | $169 | $2 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 28 | More than 62% of doctors who do this |
| Leg revascularization (restoring blood flow) | 1-10 | None |
| Pacemaker insertion or repair | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Replacement of aortic valve through the skin and femoral artery | – | 17 | 14 | – | 20 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
3,656 Original Medicare patients in 2024. Average age 73 · Under 65 15% · 85 and older 13% · Women 51% · Also on Medicaid 57% · Health risk score 2.34. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 56% · Coronary heart disease 47% · Chronic kidney disease 45% · Heart failure 41% · Atrial fibrillation 30% · Depression 30% · COPD 25% · Dementia 17% · Stroke 17% · Cancer 15%.
The office billed $1,398,083, Medicare allowed $535,601 and paid $404,483; for 8,158 services of 62 kinds; $5,045 of it was for drugs given in the office and $399,438 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 3,656 | 8,158 | 73 | 2.34 | $1,398,083 | $404,483 |
| 2023 | 3,156 | 6,648 | 73 | 2.20 | $1,153,544 | $358,881 |
| 2022 | 1,994 | 3,616 | 72 | 2.20 | $646,151 | $172,294 |
| 2021 | 635 | 1,278 | 72 | 2.33 | $440,954 | $122,096 |
| 2020 | 485 | 1,111 | 72 | 2.38 | $433,568 | $110,413 |
| 2019 | 198 | 416 | 71 | 2.10 | $173,269 | $45,627 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 30 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 91 | $67,441 | $725 |
| Return visit (30+ min) | 208 | $50,964 | $100 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 98 | $36,574 | $373 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 144 | $24,493 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 2,847 | $21,341 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $15,850 | $96 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 97 | $14,786 | $76 |
| Injection, regadenoson, 0.1 mg | 80 | $13,722 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 205 | $12,158 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 79 | $12,131 | $139 |
| New patient visit (45+ min) | 104 | $12,005 | $115 |
| Replacement of aortic valve through the skin and femoral artery | 20 | $11,639 | $582 |
| Ultrasound of both sides of head and neck blood flow | 60 | $8,701 | $145 |
| Critical care, first 30-74 minutes | 25 | $8,616 | $172 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 32 | $6,498 | $203 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 100 | $5,226 | $52 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 91 | $5,202 | $55 |
| Insertion of tube in right and left heart chambers for diagnosis with review by radiologist | 13 | $3,182 | $245 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,032 | $65 |
| Short return visit (20+ min) | 40 | $3,009 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 193 | $2,804 | $11 |
| Long return visit (40+ min) | 17 | $2,293 | $127 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 92 | $1,788 | $19 |
| New patient visit (60+ min) | 13 | $1,726 | $133 |
| Ultrasound of heart, follow-up | 31 | $635 | $20 |
| Injection, aminophyllin, up to 250 mg | 80 | $587 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 49 | $496 | $10 |
| Ultrasonic guidance for blood vessel access | 40 | $463 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 30 | $175 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 36 | $96 | $2 |
2022: 31 services
| Return visit (30+ min) | 119 | $22,282 | $103 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 22 | $16,488 | $749 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $16,082 | $158 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,736 | $13,654 | $6 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $9,804 | $377 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $8,411 | $82 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 34 | $6,945 | $198 |
| New patient visit (45+ min) | 54 | $6,808 | $126 |
| Critical care, first 30-74 minutes | 17 | $6,590 | $173 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,178 | $158 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,045 | $459 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 26 | $4,510 | $87 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $4,480 | $56 |
| Insertion of tube in right and left heart chambers, coronary artery, and bypass graft for diagnosis with review by radiologist | 12 | $3,714 | $309 |
| Short return visit (20+ min) | 56 | $3,675 | $57 |
| Insertion of tube in right and left heart chambers for diagnosis with review by radiologist | 14 | $3,324 | $237 |
| Injection, regadenoson, 0.1 mg | 17 | $3,285 | None |
| New patient visit (60+ min) | 19 | $3,245 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,396 | $104 |
| Ultrasound of both sides of head and neck blood flow | 16 | $2,303 | $144 |
| Insertion of tube in right heart chambers for measurement | 20 | $2,127 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,950 | $56 |
| Long return visit (40+ min) | 13 | $1,918 | $137 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 28 | $1,467 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 98 | $1,448 | $11 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $1,330 | $53 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 56 | $579 | $10 |
| Ultrasonic guidance for blood vessel access | 38 | $430 | $11 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 22 | $394 | $18 |
| Injection, aminophyllin, up to 250 mg | 17 | $152 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $48 | $3 |
2021: 18 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 150 | $24,840 | $162 |
| Return visit (30+ min) | 81 | $17,488 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $9,154 | $85 |
| Replacement of aortic valve through the skin and femoral artery | 14 | $8,477 | $606 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | $8,045 | $192 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $7,271 | $454 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,331 | $111 |
| New patient visit (45+ min) | 25 | $2,989 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,136 | $164 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $1,993 | $59 |
| Long return visit (40+ min) | 14 | $1,920 | $137 |
| Insertion of tube in right heart chambers for measurement | 17 | $1,904 | $106 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 219 | $1,745 | $6 |
| Short return visit (20+ min) | 21 | $1,689 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,179 | $59 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,152 | $72 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 57 | $860 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 54 | $585 | $10 |
2020: 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $17,693 | $173 |
| Replacement of aortic valve through the skin and femoral artery | 17 | $10,372 | $610 |
| Return visit (30+ min) | 60 | $9,516 | $83 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 19 | $9,169 | $458 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 38 | $7,954 | $204 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 18 | $4,875 | $271 |
| Long return visit (40+ min) | 34 | $4,474 | $118 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,374 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,075 | $85 |
| New patient visit (60+ min) | 18 | $3,019 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,988 | $166 |
| New patient visit (45+ min) | 25 | $2,783 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $1,716 | $54 |
| Insertion of tube in right heart chambers for measurement | 16 | $1,560 | $97 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 154 | $1,346 | $7 |
| Short return visit (20+ min) | 21 | $1,194 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,120 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 60 | $968 | $13 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $911 | $83 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 56 | $567 | $10 |
| Ultrasound of heart, follow-up | 18 | $468 | $21 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $102 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $64 | $3 |
2019: 14 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $7,693 | $171 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 22 | $4,517 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,359 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,261 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,762 | $110 |
| New patient visit (45+ min) | 14 | $1,739 | $124 |
| Insertion of tube in right heart chambers for measurement | 14 | $1,462 | $104 |
| Long return visit (40+ min) | 12 | $1,309 | $109 |
| Return visit (30+ min) | 13 | $1,193 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $962 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $821 | $59 |
| Short return visit (20+ min) | 11 | $670 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 33 | $423 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $129 | $10 |
Medicaid work
$87,526 in 2024
Medicaid paid $87,526 for 14,589 billed services this clinician did in 2024, up to 628 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 291 | $49,882 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 7,253 | $10,870 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 860 | $9,077 |
| External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional | 222 | $7,109 |
| New patient visit (45+ min) | 293 | $3,342 |
| Return visit (30+ min) | 909 | $2,695 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 251 | $1,157 |
| 1ST HOSP IP/OBS HIGH 75 | 74 | $1,095 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,054 | $862 |
| CARDIOVASCULAR STRESS TEST | 190 | $674 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 124 | $282 |
| XTRNL MOBILE CV TELEMETRY W/I&REPORT 30 DAYS | 222 | $224 |
| 2024 | 14,589 | 29 | 628 | $87,526 |
| 2023 | 12,372 | 28 | 525 | $70,230 |
| 2022 | 4,014 | 8 | 364 | $6,615 |
| 2021 | 431 | 5 | 31 | $38,067 |
| 2020 | 270 | 5 | 28 | $44,275 |
| 2019 | 65 | 2 | 18 | $12,951 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 227 | $37,639 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 6,834 | $8,686 |
| External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional | 278 | $8,270 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 635 | $5,824 |
| Return visit (30+ min) | 643 | $2,476 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 312 | $1,491 |
| New patient visit (45+ min) | 392 | $1,024 |
| CARDIOVASCULAR STRESS TEST | 208 | $932 |
| 1ST HOSP IP/OBS HIGH 75 | 41 | $818 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 716 | $764 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 145 | $726 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 47 | $428 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 3,399 | $2,346 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 173 | $2,127 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $664 |
| Return visit (30+ min) | 96 | $645 |
| New patient visit (45+ min) | 97 | $359 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 190 | $260 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $215 |
| CARDIOVASCULAR STRESS TEST | 14 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 118 | $34,836 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 56 | $2,148 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 165 | $654 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $430 |
| Return visit (30+ min) | 62 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 165 | $43,870 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 58 | $349 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $56 |
| Short return visit (20+ min) | 16 | $0 |
| Return visit (30+ min) | 17 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 50 | $12,585 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $367 |
Drugs they prescribed that Part D paid
$514,762
Pharmacies billed $514,762 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,278) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,732 generic and 546 brand-name prescriptions · $514,762 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Entresto | 158 | $187,946 | $1,190 |
| Eliquis | 123 | $124,275 | $1,010 |
| Repatha Sureclick | 106 | $71,258 | $672 |
| Farxiga | 40 | $39,150 | $979 |
| Brilinta | 30 | $28,454 | $948 |
See all 29 drugs
| Entresto | 158 | $187,946 | $1,190 |
| Eliquis | 123 | $124,275 | $1,010 |
| Repatha Sureclick | 106 | $71,258 | $672 |
| Farxiga | 40 | $39,150 | $979 |
| Brilinta | 30 | $28,454 | $948 |
| Jardiance | 19 | $21,593 | $1,136 |
| Rosuvastatin | 431 | $8,111 | $19 |
| Metoprolol | 303 | $4,393 | $14 |
| Ezetimibe | 82 | $3,129 | $38 |
| Ranolazine Er | 14 | $2,012 | $144 |
| Atorvastatin | 206 | $2,002 | $10 |
| Carvedilol | 91 | $734 | $8 |
| Potassium Chloride | 24 | $730 | $30 |
| Nifedipine Er | 12 | $658 | $55 |
| Amiodarone | 14 | $656 | $47 |
| Furosemide | 108 | $498 | $5 |
| Bumetanide | 12 | $479 | $40 |
| Pravastatin | 26 | $449 | $17 |
| Losartan | 49 | $436 | $9 |
| Nitroglycerin | 30 | $434 | $14 |
| Isosorbide Mononitrate Er | 34 | $404 | $12 |
| Lisinopril | 43 | $402 | $9 |
| Hydralazine | 14 | $385 | $28 |
| Spironolactone | 48 | $376 | $8 |
| Clopidogrel | 55 | $361 | $7 |
| Amlodipine Besylate | 44 | $296 | $7 |
| Metoprolol | 35 | $259 | $7 |
| Pantoprazole | 14 | $92 | $7 |
| Hydrochlorothiazide | 17 | $39 | $2 |
Year by year
| 2024 | 2,278 | 431 | 0% (0) | 24% | $514,762 |
| 2023 | 1,240 | 249 | 0% (0) | 22% | $318,414 |
| 2022 | 657 | 160 | 0% (0) | 16% | $100,672 |
| 2021 | 850 | 153 | 0% (0) | 14% | $93,048 |
| 2020 | 785 | 119 | 0% (0) | 15% | $57,701 |
| 2019 | 181 | 55 | 0% (0) | 11% | $8,556 |
| 2018 | 343 | 52 | 0% (0) | 29% | $33,804 |
| 2017 | 377 | 43 | 0% (0) | 31% | $25,555 |
| 2016 | 188 | 33 | None | 28% | $5,198 |
| 2015 | 71 | 22 | None | 23% | $2,009 |
| 2014 | 161 | 20 | None | None | $10,778 |
| 2013 | 63 | 14 | None | None | $3,985 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Entresto | 90 | $136,561 | $1,517 |
| Eliquis | 58 | $73,399 | $1,266 |
| Farxiga | 20 | $25,830 | $1,292 |
| Repatha Sureclick | 31 | $20,143 | $650 |
| Xarelto | 12 | $12,992 | $1,083 |
| Brilinta | 13 | $11,527 | $887 |
| Atorvastatin | 234 | $6,190 | $26 |
| Metoprolol | 158 | $4,622 | $29 |
| Rosuvastatin | 139 | $3,719 | $27 |
| Ezetimibe | 22 | $1,130 | $51 |
| Furosemide | 76 | $838 | $11 |
| Clopidogrel | 51 | $782 | $15 |
| Carvedilol | 32 | $635 | $20 |
| Isosorbide Mononitrate Er | 27 | $626 | $23 |
| Potassium Chloride | 19 | $531 | $28 |
| Losartan | 31 | $496 | $16 |
| Spironolactone | 21 | $462 | $22 |
| Metoprolol | 24 | $449 | $19 |
| Amiodarone | 13 | $344 | $26 |
| Nitroglycerin | 19 | $335 | $18 |
| Lisinopril | 25 | $330 | $13 |
| Amlodipine Besylate | 24 | $306 | $13 |
| Pravastatin | 18 | $294 | $16 |
2022: 14 drugs
| Entresto | 20 | $33,115 | $1,656 |
| Eliquis | 41 | $32,477 | $792 |
| Rosuvastatin | 87 | $1,974 | $23 |
| Metoprolol | 89 | $1,715 | $19 |
| Atorvastatin | 99 | $1,713 | $17 |
| Ezetimibe | 14 | $765 | $55 |
| Clopidogrel | 36 | $357 | $10 |
| Carvedilol | 22 | $336 | $15 |
| Furosemide | 44 | $303 | $7 |
| Losartan | 26 | $275 | $11 |
| Spironolactone | 16 | $270 | $17 |
| Potassium Chloride | 13 | $171 | $13 |
| Lisinopril | 24 | $127 | $5 |
| Amlodipine Besylate | 16 | $120 | $8 |
2021: 19 drugs
| Eliquis | 45 | $32,902 | $731 |
| Xarelto | 20 | $18,084 | $904 |
| Entresto | 13 | $17,725 | $1,363 |
| Brilinta | 18 | $10,328 | $574 |
| Rosuvastatin | 81 | $2,681 | $33 |
| Atorvastatin | 144 | $2,169 | $15 |
| Metoprolol | 93 | $1,689 | $18 |
| Ezetimibe | 13 | $748 | $58 |
| Carvedilol | 70 | $570 | $8 |
| Clopidogrel | 42 | $413 | $10 |
| Losartan | 29 | $292 | $10 |
| Nitroglycerin | 14 | $276 | $20 |
| Nifedipine Er | 11 | $271 | $25 |
| Lisinopril | 54 | $266 | $5 |
| Isosorbide Mononitrate Er | 19 | $255 | $13 |
| Furosemide | 48 | $245 | $5 |
| Potassium Chloride | 21 | $185 | $9 |
| Amlodipine Besylate | 28 | $184 | $7 |
| Metoprolol | 12 | $61 | $5 |
2020: 13 drugs
| Eliquis | 33 | $21,510 | $652 |
| Brilinta | 18 | $11,122 | $618 |
| Metoprolol | 66 | $2,144 | $32 |
| Atorvastatin | 127 | $2,086 | $16 |
| Rosuvastatin | 63 | $774 | $12 |
| Carvedilol | 111 | $666 | $6 |
| Potassium Chloride | 41 | $518 | $13 |
| Clopidogrel | 45 | $415 | $9 |
| Furosemide | 68 | $390 | $6 |
| Losartan | 18 | $209 | $12 |
| Lisinopril | 36 | $176 | $5 |
| Amlodipine Besylate | 28 | $148 | $5 |
| Metoprolol | 23 | $119 | $5 |
2019: 5 drugs
| Brilinta | 11 | $5,322 | $484 |
| Clopidogrel | 48 | $666 | $14 |
| Atorvastatin | 39 | $606 | $16 |
| Metoprolol | 13 | $304 | $23 |
| Carvedilol | 19 | $172 | $9 |
2018: 9 drugs
| Brilinta | 51 | $21,511 | $422 |
| Eliquis | 14 | $5,927 | $423 |
| Metoprolol | 55 | $1,272 | $23 |
| Atorvastatin | 67 | $829 | $12 |
| Clopidogrel | 51 | $635 | $12 |
| Nifedipine Er | 14 | $148 | $11 |
| Carvedilol | 16 | $87 | $5 |
| Lisinopril | 13 | $80 | $6 |
| Hydrochlorothiazide | 16 | $27 | $2 |
2017: 9 drugs
| Brilinta | 42 | $14,134 | $337 |
| Eliquis | 20 | $7,862 | $393 |
| Atorvastatin | 79 | $719 | $9 |
| Metoprolol | 43 | $525 | $12 |
| Nifedipine Er | 11 | $200 | $18 |
| Carvedilol | 36 | $173 | $5 |
| Furosemide | 30 | $156 | $5 |
| Lisinopril | 39 | $146 | $4 |
| Clopidogrel | 17 | $115 | $7 |
2016: 5 drugs
| Metoprolol | 12 | $352 | $29 |
| Atorvastatin | 32 | $283 | $9 |
| Lisinopril | 32 | $109 | $3 |
| Furosemide | 32 | $106 | $3 |
| Carvedilol | 18 | $103 | $6 |
2015: 1 drug
| Atorvastatin | 11 | $184 | $17 |
2014: 4 drugs
| Nexium | 12 | $2,921 | $243 |
| Lisinopril | 11 | $70 | $6 |
| Amlodipine Besylate | 19 | $53 | $3 |
| Hydrochlorothiazide | 12 | $47 | $4 |
Money from drug and device companies
$2,185 in 2025
| 2025 | 17 | 105 | None | $2,185 |
| 2024 | 23 | 115 | None | $3,165 |
| 2023 | 19 | 102 | None | $2,696 |
| 2022 | 17 | 84 | None | $3,839 |
| 2021 | 6 | 16 | None | $1,495 |
| 2020 | 5 | 22 | None | $1,873 |
| 2019 | 8 | 113 | None | $6,837 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Repatha | $418 | 27 payments
|
| Abbott Laboratories | Navitor | $229 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $199 | 19 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $192 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $148 | 7 payments
|
| Abiomed | None | $144 | 1 payment
|
See all 105 published payments
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-12-22 | Lifevest | $12 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-22 | Kerendia | $29 |
| Amgen | Meals · 2025-12-22 | Repatha | $11 |
| Pfizer | Meals · 2025-12-16 | Vyndaqel | $22 |
| Boston Scientific | Meals · 2025-12-15 | Watchman Flx | $29 |
| Alnylam Pharmaceuticals | Meals · 2025-12-08 | Amvuttra | $20 |
| Amgen | Meals · 2025-12-04 | Repatha | $8 |
| Reflow Medical | Meals · 2025-12-03 | None | $11 |
| Abiomed | Meals · 2025-11-21 | None | $144 |
| Amgen | Meals · 2025-11-18 | Repatha | $16 |
| Boston Scientific | Meals · 2025-11-17 | Watchman Flx | $28 |
| Boston Scientific | Meals · 2025-11-14 | Accolade Sr | $32 |
| Amgen | Meals · 2025-11-12 | Repatha | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-11-10 | Lifevest | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-10 | Jardiance | $23 |
| Medtronic | Meals · 2025-11-03 | Corevalve Evolut R | $26 |
| Amgen | Meals · 2025-10-31 | Repatha | $9 |
| Pfizer | Meals · 2025-10-28 | Vyndaqel | $17 |
| Actelion Pharmaceuticals US | Meals · 2025-10-23 | Uptravi | $16 |
| Boston Scientific | Meals · 2025-10-23 | Watchman Flx | $29 |
| Merck Sharp & Dohme | Meals · 2025-10-22 | Capvaxive | $14 |
| Actelion Pharmaceuticals US | Meals · 2025-10-21 | Uptravi | $17 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Leqvio | $23 |
| Amgen | Meals · 2025-10-14 | Repatha | $6 |
| Amgen | Meals · 2025-10-09 | Repatha | $2 |
| Abbott Laboratories | Meals · 2025-10-09 | Mitraclip | $18 |
| Abbott Laboratories | Meals · 2025-10-08 | Navitor | $175 |
| Alnylam Pharmaceuticals | Meals · 2025-10-06 | Amvuttra | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-03 | Jardiance | $23 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-10-02 | Lifevest | $21 |
| Abbott Laboratories | Meals · 2025-09-08 | Perclose Prostyle | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-04 | Kerendia | $14 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Leqvio | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-28 | Lifevest | $20 |
| Alnylam Pharmaceuticals | Meals · 2025-08-26 | Amvuttra | $24 |
| GlaxoSmithKline | Meals · 2025-08-25 | Shingrix | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-21 | Jardiance | $20 |
| Amgen | Meals · 2025-08-20 | Repatha | $15 |
| Amgen | Meals · 2025-08-13 | Repatha | $14 |
| Novartis Pharmaceuticals | Meals · 2025-08-08 | Leqvio | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-08 | Leqvio | $1 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-29 | Jardiance | $18 |
| Amgen | Meals · 2025-07-29 | Repatha | $7 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-23 | Lifevest | $18 |
| Pfizer | Meals · 2025-07-22 | Vyndaqel | $22 |
| Alnylam Pharmaceuticals | Meals · 2025-07-18 | Amvuttra | $24 |
| Amgen | Meals · 2025-07-18 | Repatha | $10 |
| Novartis Pharmaceuticals | Meals · 2025-07-10 | Leqvio | $23 |
| Novartis Pharmaceuticals | Meals · 2025-07-10 | Leqvio | $1 |
| Abbott Laboratories | Meals · 2025-07-01 | Perclose Prostyle | $19 |
| Amgen | Meals · 2025-06-27 | Repatha | $17 |
| Amgen | Meals · 2025-06-16 | Repatha | $18 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-13 | Jardiance | $19 |
| Novartis Pharmaceuticals | Meals · 2025-06-12 | Leqvio | $18 |
| Novartis Pharmaceuticals | Meals · 2025-06-12 | Leqvio | $1 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-10 | Kerendia | $25 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-03 | Lifevest | $23 |
| Actelion Pharmaceuticals US | Meals · 2025-05-30 | Uptravi | $27 |
| Novartis Pharmaceuticals | Meals · 2025-05-28 | Leqvio | $1 |
| Amgen | Meals · 2025-05-27 | Repatha | $11 |
| Amgen | Meals · 2025-05-22 | Repatha | $4 |
| Alnylam Pharmaceuticals | Meals · 2025-05-17 | Amvuttra | $24 |
| Amgen | Meals · 2025-05-15 | Repatha | $8 |
| Merck Sharp & Dohme | Meals · 2025-05-14 | Verquvo | $23 |
| Medtronic | Meals · 2025-05-08 | Azure Xt Dr Mri Surescan | $28 |
| Novartis Pharmaceuticals | Meals · 2025-05-06 | Leqvio | $8 |
| Novartis Pharmaceuticals | Meals · 2025-05-06 | Leqvio | $5 |
| Novartis Pharmaceuticals | Meals · 2025-05-06 | Leqvio | $2 |
| Amgen | Meals · 2025-05-05 | Repatha | $17 |
| Medtronic | Meals · 2025-04-30 | Azure Xt Dr Mri Surescan | $19 |
| Medtronic | Meals · 2025-04-26 | Azure Xt Dr Mri Surescan | $35 |
| Merck Sharp & Dohme | Meals · 2025-04-25 | Verquvo | $24 |
| Novo Nordisk | Meals · 2025-04-23 | None | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-21 | Kerendia | $23 |
| Amgen | Meals · 2025-04-18 | Repatha | $9 |
| Novartis Pharmaceuticals | Meals · 2025-04-11 | Leqvio | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-04-10 | Lifevest | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-07 | Jardiance | $20 |
| Medtronic | Meals · 2025-04-04 | Azure Xt Dr Mri Surescan | $27 |
| Alnylam Pharmaceuticals | Meals · 2025-03-31 | Amvuttra | $21 |
| Amgen | Meals · 2025-03-27 | Repatha | $11 |
| Merck Sharp & Dohme | Meals · 2025-03-26 | Verquvo | $26 |
| Novo Nordisk | Meals · 2025-03-25 | None | $17 |
| Pfizer | Meals · 2025-03-20 | Vyndaqel | $20 |
| Amgen | Meals · 2025-03-14 | Repatha | $21 |
| Amgen | Meals · 2025-03-12 | Repatha | $5 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Leqvio | $16 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Leqvio | $1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-26 | Lifevest | $25 |
| Amgen | Meals · 2025-02-25 | Repatha | $12 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-20 | Camzyos | $19 |
| Amgen | Meals · 2025-02-14 | Repatha | $5 |
| Amgen | Meals · 2025-02-12 | Repatha | $10 |
| Amgen | Meals · 2025-02-12 | Repatha | $125 |
| Actelion Pharmaceuticals US | Meals · 2025-02-10 | Uptravi | $21 |
| Amgen | Meals · 2025-02-05 | Repatha | $12 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Leqvio | $1 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Leqvio | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-31 | Kerendia | $24 |
| Merck Sharp & Dohme | Meals · 2025-01-29 | Verquvo | $17 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-01-28 | Lifevest | $21 |
| Amgen | Meals · 2025-01-24 | Repatha | $16 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-21 | Jardiance | $25 |
| Novartis Pharmaceuticals | Meals · 2025-01-07 | Leqvio | $18 |
| Novartis Pharmaceuticals | Meals · 2025-01-07 | Leqvio | $1 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,165
| Amgen | Repatha | $976 | 36 payments
|
| Medtronic | Micra | $374 | 5 payments
|
| Boston Scientific | Emerge Push | $291 | 6 payments
|
| Lexicon Pharmaceuticals | Inpefa | $233 | 6 payments
|
| Novartis Pharmaceuticals | Leqvio | $220 | 17 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $171 | 10 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $128 | 1 payment
|
| Biotronik | Biomonitor | $89 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $88 | 4 payments
|
| CVRx | Barostim Neo System | $86 | 6 payments
|
| Abbott Laboratories | Jot Dx | $76 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $67 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $57 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $50 | 2 payments
|
| Scpharmaceuticals | Furoscix | $45 | 2 payments
|
| Daiichi Sankyo | Injectafer | $38 | 2 payments
|
| Chiesi USA | Kengreal | $33 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $30 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $27 | 1 payment
|
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $25 | 1 payment
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $24 | 1 payment
|
| Esperion Therapeutics | Nexletol | $22 | 1 payment
|
| Kestra Medical Technology Services | Assure Wcd | $15 | 1 payment
|
2023: $2,696
| Amgen | Repatha | $897 | 32 payments
|
| Abbott Laboratories | Mitraclip | $393 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $247 | 9 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $152 | 2 payments
|
| Novo Nordisk | None | $134 | 14 payments
|
| Esperion Therapeutics | Nexletol | $119 | 6 payments
|
| Medtronic | Corevalve Evolut R | $104 | 1 payment
|
| CVRx | Barostim Neo System | $103 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $97 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $92 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $82 | 5 payments
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $69 | 2 payments
|
| Abiomed | Impella | $59 | 1 payment
|
| Scpharmaceuticals | Furoscix | $41 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $32 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $29 | 2 payments
|
| Pfizer | Eliquis | $17 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $15 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $14 | 1 payment
|
2022: $3,839
| Medtronic | Corevalve Evolut R | $1,579 | 11 payments
|
| Amgen | Repatha | $732 | 28 payments
|
| Abiomed | Impella | $419 | 17 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $306 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $179 | 4 payments
|
| Abbott Laboratories | Mitraclip | $165 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $150 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $86 | 5 payments
|
| Esperion Therapeutics | Nexletol | $39 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $32 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $31 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $22 | 1 payment
|
| Boston Scientific | General - Brady | $22 | 1 payment
|
| Amarin Pharma | Vascepa | $22 | 1 payment
|
| Penumbra | Indigo System | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $19 | 1 payment
|
| Pfizer | Eliquis | $17 | 1 payment
|
2021: $1,495
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $1,248 | 7 payments
|
| Penumbra | Indigo System | $100 | 1 payment
|
| Abbott Laboratories | Perclose Proglide Suture Mediated Closure System | $67 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $46 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $23 | 1 payment
|
| Boston Scientific | Watchman | $11 | 1 payment
|
2020: $1,873
| Abbott Laboratories | Tendyne Mitral Valve System | $1,421 | 12 payments
|
| Boston Scientific | Watchman | $379 | 6 payments
|
| Amgen | Repatha | $32 | 1 payment
|
| Edwards Lifesciences | None | $27 | 2 payments
|
| Medtronic Vascular | 3f | $14 | 1 payment
|
2019: $6,837
| Abbott Laboratories | Xience V Coronary Stent System | $2,808 | 27 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $1,900 | 54 payments
|
| Boston Scientific | Watchman | $1,538 | 21 payments
|
| Medtronic Vascular | Corevalve Evolut | $264 | 4 payments
|
| United Therapeutics | Remodulin | $116 | 3 payments
|
| Acist Medical Systems | Cvi Systems | $76 | 2 payments
|
| Philips Electronics North America | Elca | $70 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $66 | 1 payment
|
Professional record
- NPI
- 1295039360
- Licence
- CA A123839California A123839: Current · expires 2028-05-31
- Group
- Fresno Community Hospital and Medical Center · California Heart Medical Associates, Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2011-01-04
- NPI last updated
- 2021-05-28
- NPI record certified
- 2021-05-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 729 N Medical Center Dr W Ste 111, Clovis, CA, 93611